Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C18H19NO3 |
| Molecular Weight | 297.3484 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C3C(CC4(C=CC(=O)C=C4)C3=C1O)N(C)CC2
InChI
InChIKey=PNJUPRNTSWJWAX-UHFFFAOYSA-N
InChI=1S/C18H19NO3/c1-19-8-5-11-9-14(22-2)17(21)16-15(11)13(19)10-18(16)6-3-12(20)4-7-18/h3-4,6-7,9,13,21H,5,8,10H2,1-2H3
| Molecular Formula | C18H19NO3 |
| Molecular Weight | 297.3484 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Glaziovine is a pro-aporphine alkaloid with neuropharmacological properties. Glaziovine is an alkaloid, originally isolated from Ocotea glaziovii (Lauraceae), belonging to the fairly small proaporphine family. In the early 1970's its pharmacology was explored extensively by a pharmaceutical company (Simes S.p.A., Milano), and was registered as a tranquilizer under the trademark Suavedol®. It is also reported to possess anti-ulcer properties in humans.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL613497 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17723297 |
0.008 mM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
441 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/668777/ |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLAZIOVINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: |
|
1211 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/668777/ |
20 mg single, intravenous dose: 20 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
GLAZIOVINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: |
Doses
| Dose | Population | Adverse events |
|---|---|---|
20 mg 1 times / day multiple, oral Highest studied dose Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
|
20 mg single, intravenous Highest studied dose Dose: 20 mg Route: intravenous Route: single Dose: 20 mg Sources: |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
|
20 mg single, oral Highest studied dose |
healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/668777
Glaziovine-14C 20 mg was administered in capsules (oral route) and in vials (i.v. route).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17723297
Glaziovine exhibits high inhibitory potential against HBsAg with IC50 value of 0.008 mM.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:16:09 GMT 2025
by
admin
on
Mon Mar 31 18:16:09 GMT 2025
|
| Record UNII |
KE7J8A65P6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29701
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C007847
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
KE7J8A65P6
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
C73193
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
3831
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
65631
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
100000080420
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
17127-48-9
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL1980854
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
DTXSID90864739
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
146052
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY | |||
|
SUB07911MIG
Created by
admin on Mon Mar 31 18:16:09 GMT 2025 , Edited by admin on Mon Mar 31 18:16:09 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |